This page lists some of the clinical trials that are available for patients with PSC. This list is not extensive, and there may be other trials which we have not listed. It is always recommended to contact your GP/Consultant for advice about clinical trials.
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
  • This research study is sponsored by Dr. Falk Pharma GmbH.
  • Norursodeoxycholic acid (norUDCA) is a new drug, currently under investigation for the treatment of PSC.
  • The aim of this research study is to show the superiority of norursodeoxycholic acid compared to a placebo (capsules without active drug), with regard to prevention of disease progression of primary sclerosing cholangitis.
  • Patient’s participation in this study will last up to 202 weeks.
  • The inclusion/exclusion criteria for this study is very specific. Please speak with your GP/Consultant for further advise.
  • The study is currently taking place at University Hospitals Birmingham NHS Foundation Trust, by Dr Palak Trivedi.
  • Further information about this trial can be found here: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003367-19/AT

 

An Adaptive,Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis
  • This research study is sponsored by University of Birmingham.
  • The aim of this research study is split into two parts. Part 1 aims to determine dose safety of ORBCEL-C (selected Mesenchymal stromal cells derived from human umbilical cord).
  • Once the dose safety is determined from part 1, the aim of part 2 is to determine safety and activity outcomes of ORBCEL-C.
  • The inclusion/exclusion criteria for this study is very specific. Please speak with your GP/Consultant for further advise.
  • The research study aims to recruit 56 patients. The study is currently taking place at University Hospitals Birmingham NHS Foundation Trust, by Dr Palak Trivedi.
  • Please contact Rebecca Storey, on 01213718109  or r.storey@bham.ac.uk for further information.
  • Further information about this trial can be found here: https://clinicaltrials.gov/ct2/show/NCT02997878